Unlocking biased GPCR signaling to guide safer, smarter drugs
Official title: Unlocking the potential of beta-arrestin isoform bias as a novel dimension of drug design
Funded at University of Wyoming · NIH-11430135 · Data updated 2026-11-12
A research program from the University of Wyoming aims to understand how different beta-arrestin proteins shape GPCR signaling to help design drugs with better therapeutic effects and fewer side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wyoming NIH-funded |
| Lab location | 1 site (Laramie, United States) |
| Project start | September 1, 2026 |
| Project end | April 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $349,483 |
| NIH project number | 1R35GM166239-01 |
| Project ID | NIH-11430135 on NIH RePORTER |
Who could benefit from this research
✓Could help
Candidates with conditions related to GPCR signaling–linked diseases may benefit from future therapies developed using these insights.
✕Less likely to help
Patients without conditions involving GPCR signaling may not directly benefit from this basic research.
What this research studies
GPCRs control many body processes. This project focuses on how activating GPCRs can preferentially trigger either G proteins or beta-arrestin pathways, with a special look at beta-arrestin isoforms. By using a novel drug-screening approach, the team hopes to map how these choices affect disease-relevant signals and outcomes. The work seeks to translate basic insights into principles for creating next-generation medicines. It’s a collaborative effort to guide safer, more effective drug design.
Why it matters
Potential benefit: If successful, this work could inform the development of GPCR-targeted therapies with improved efficacy and reduced adverse effects.
How similar studies have gone: Previous work showed that pathway bias can influence drug effects, but understanding isoform-specific roles may yield new therapeutic directions.
Where this research is happening
-
University of Wyoming
Laramie, United States Active
Researchers
- Principal investigator: French, Alexander Robert — University of Wyoming
- Study coordinator: French, Alexander Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.